Clinical-proteomic classification and precision treatment strategy of chordoma

Huabin Yin,Jinbo Hu,Jianxuan Gao,Tong Su,Jiali Jin,Cong Jiang,Wenxuan Yin,Xiaowen Xu,Zhengyan Chang,Wei Sun,Zhengdong Cai,Wang Zhou,Ping Wang,Jun Lin,Dianwen Song,Tong Meng

DOI: https://doi.org/10.1016/j.xcrm.2024.101757

2024-10-15

Abstract:Chordoma is a rare and heterogeneous mesenchymal malignancy, with distinct clinical and biological behaviors. Till now, its comprehensive clinical-molecular characteristics and accurate molecular classification remain obscure. In this research, we enroll 102 patients with chordoma and describe their clinical, imageological, and histopathological features. Through tandem mass tag-based proteomic analysis and nonnegative matrix factorization clustering, we classify chordoma into three molecular subtypes: bone microenvironment-dominant, mesenchymal-derived, and mesenchymal-to-epithelial transition-mediated pattern. The three subtypes exhibit discrete clinical prognosis and distinct biological attributes of osteoclastogenesis and immunogenicity, oxidative phosphorylation, and receptor tyrosine kinase activation, suggesting targeted therapeutic strategies of denosumab, S-Gboxin, and anlotinib, respectively. Notably, these approaches demonstrate positive treatment outcomes for each subtype in vitro and in vivo. Altogether, this work sheds light on the clinical-proteomic characteristics of chordoma and provides a candidate precision treatment strategy for chordoma according to molecular classification, underscoring their potential for clinical application.